Home › NCT05437536
The Severe Von Willebrand Disease (sVWD) Patient Registry
The Severe Von Willebrand Disease Patient Registry: A Longitudinal Natural History and Patient Outcomes Study
Who can join
All ages · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Anyone meeting the diagnostic classification for von Willebrand disease 2. Any VWF antigen or activity: a. Result \<20% regardless of bleeding phenotype, or b. Result \<30% with excessive bleeding symptoms including: i. Bleeding that resulted in hospitalization, required surgical procedure, red blood cell transfusion, Hemoglobin decrease \>2g/dL, or ii. Intracranial, intraspinal, pericardial, retroperitoneal, intramuscular bleeding with compartment syndrome, or iii. Persistent or recurrent bleeding that is disruptive of work or school. 3. Provide informed consent by participant or legally authorized representative 4. Be willing and able to comply with study procedures and data collection 5. Reside in the United States NOTE: For inclusion criteria 1 and 2, it is not expected that participants will submit evidence of clinical diagnosis at screening; a participant's own confirmation that they have severe VWD will be sufficient for meeting the enrollment requirement and obtaining access to the registry. Laboratory values will be provided during the conduct of the study, and participants with VWF antigen or activity not meeting inclusion criterion 2 may be excluded from data analysis on a case-by-case basis in consultation with a subcommittee of the VWD Connect Foundation Medical and Scientific Advisory Board. Exclusion Criteria: 1\. Have a clinical diagnosis of acquired VWD
About the study
A web-based registry will be created by the sponsor, VWD Connect Foundation (VCF), to collect data on patients with severe Von Willebrand Disease (sVWD). Data will be self-reported by patients and/or collected by registry personnel, as appropriate. The purpose of the sVWD Patient Registry is to create a database of well-characterized (with respect to demographics, medical history, symptoms, laboratory and genetic data, etc.) patients with sVWD for participation in retrospective and prospective research.
Sponsor: VWD Connect Foundation · Participants: 400 · Started: Dec 10, 2021
Contact the study team
- Christina Morgenthaler, MS, MBA · Phone: (279) 346-6202
Official record on ClinicalTrials.gov — NCT05437536
Locations in the U.S.
| Florida | VWD Connect Foundation, Wellington |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.